In addition, the PD-L1 expression of more than 10% on tumor tissues can serve as a biomarker to identify the NSCLC patient populations that might respond positively to PD-1/ PD-L1 antibody therapy, and thereby helping many patients to make a informed decision about this high cost immunotherapy. This evidence concerns the gene CD274 and neoplasm.